SG11201604954YA - Novel tetrahydropyridopyrimidine compound or salt thereof - Google Patents

Novel tetrahydropyridopyrimidine compound or salt thereof

Info

Publication number
SG11201604954YA
SG11201604954YA SG11201604954YA SG11201604954YA SG11201604954YA SG 11201604954Y A SG11201604954Y A SG 11201604954YA SG 11201604954Y A SG11201604954Y A SG 11201604954YA SG 11201604954Y A SG11201604954Y A SG 11201604954YA SG 11201604954Y A SG11201604954Y A SG 11201604954YA
Authority
SG
Singapore
Prior art keywords
salt
tetrahydropyridopyrimidine compound
novel
novel tetrahydropyridopyrimidine
compound
Prior art date
Application number
SG11201604954YA
Other languages
English (en)
Inventor
Kazuhisa Minamiguchi
Shigeo Okajima
Shinichi Aoki
Masanori Asai
Takahiro Asai
Hiroyoshi Yamanaka
Suguru Dohi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11201604954YA publication Critical patent/SG11201604954YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201604954YA 2014-05-29 2015-05-28 Novel tetrahydropyridopyrimidine compound or salt thereof SG11201604954YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014111147 2014-05-29
PCT/JP2015/065425 WO2015182712A1 (fr) 2014-05-29 2015-05-28 Nouveau composé tétrahydropyridopyrimidine ou l'un de ses sels

Publications (1)

Publication Number Publication Date
SG11201604954YA true SG11201604954YA (en) 2016-07-28

Family

ID=54699035

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201604954YA SG11201604954YA (en) 2014-05-29 2015-05-28 Novel tetrahydropyridopyrimidine compound or salt thereof

Country Status (21)

Country Link
US (3) US9662333B2 (fr)
EP (1) EP3150599B1 (fr)
JP (1) JP5851663B1 (fr)
KR (1) KR101708604B1 (fr)
CN (1) CN106103434B (fr)
AU (2) AU2015268494B2 (fr)
BR (1) BR112016027691B1 (fr)
CA (1) CA2941668C (fr)
DK (1) DK3150599T3 (fr)
ES (1) ES2703168T3 (fr)
HU (1) HUE041645T2 (fr)
MX (1) MX360496B (fr)
MY (1) MY162886A (fr)
PH (1) PH12016501252A1 (fr)
PL (1) PL3150599T3 (fr)
PT (1) PT3150599T (fr)
RU (1) RU2636310C1 (fr)
SG (1) SG11201604954YA (fr)
TR (1) TR201819419T4 (fr)
TW (1) TWI585087B (fr)
WO (1) WO2015182712A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3150599B1 (fr) 2014-05-29 2018-10-24 Taiho Pharmaceutical Co., Ltd. Nouveau composé tétrahydropyridopyrimidine ou l'un de ses sels
EP3381916B1 (fr) 2015-11-27 2020-04-15 Taiho Pharmaceutical Co., Ltd. Composé pyrimidine condensé ou sel de celui-ci
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
UA124273C2 (uk) * 2016-11-28 2021-08-18 Тейдзін Фарма Лімітед КРИСТАЛІЧНА ФОРМА ПІРИДО[3,4-d]ПІРИМІДИНОВОГО ПОХІДНОГО АБО ЙОГО СОЛЬВАТ
CN106727588A (zh) * 2016-11-30 2017-05-31 顾克斌 一种治疗急性肺损伤的药物组合物
CN108484594B (zh) * 2018-02-09 2020-08-04 福建医科大学 一种烷氧基取代四氢吡啶并嘧啶类化合物或其可用盐及其制备方法与应用
JPWO2020110974A1 (ja) 2018-11-26 2021-10-07 大鵬薬品工業株式会社 線維芽細胞増殖因子受容体阻害剤と内分泌療法との併用による内分泌療法が適用される腫瘍の治療及び予防方法
WO2021058017A1 (fr) * 2019-09-29 2021-04-01 Beigene, Ltd. Dégradation du récepteur des androgènes (ar) par conjugaison d'antagonistes ar avec un ligand de ligase e3 et procédés d'utilisation
WO2022212631A1 (fr) * 2021-03-31 2022-10-06 Taiho Pharmaceutical Co., Ltd. Traitement de patients atteints d'un cancer métastatique de la prostate résistant à la castration avec un antagoniste du récepteur des androgènes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US7312330B2 (en) * 2003-12-24 2007-12-25 Renovis, Inc. Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US20060128710A1 (en) 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
AU2006205066B2 (en) * 2005-01-10 2012-05-17 Acadia Pharmaceuticals Inc. Aminophenyl derivatives as selective androgen receptor modulators
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
CN101277700B (zh) 2005-08-04 2013-02-20 詹森药业有限公司 作为5-羟色胺受体调节剂的嘧啶化合物
US8507491B2 (en) 2008-08-25 2013-08-13 Irm Llc Compounds and compositions as hedgehog pathway inhibitors
EP3150599B1 (fr) * 2014-05-29 2018-10-24 Taiho Pharmaceutical Co., Ltd. Nouveau composé tétrahydropyridopyrimidine ou l'un de ses sels

Also Published As

Publication number Publication date
BR112016027691A2 (pt) 2017-08-15
CN106103434B (zh) 2019-05-10
US9662333B2 (en) 2017-05-30
WO2015182712A1 (fr) 2015-12-03
HUE041645T2 (hu) 2019-05-28
AU2015268494A1 (en) 2016-08-18
US20160310496A1 (en) 2016-10-27
MX360496B (es) 2018-11-05
JP5851663B1 (ja) 2016-02-03
US20160244444A1 (en) 2016-08-25
JPWO2015182712A1 (ja) 2017-04-20
AU2017219032B2 (en) 2018-11-08
MY162886A (en) 2017-07-20
AU2017219032A1 (en) 2017-09-14
CN106103434A (zh) 2016-11-09
CA2941668C (fr) 2019-04-16
PT3150599T (pt) 2018-12-28
ES2703168T3 (es) 2019-03-07
TWI585087B (zh) 2017-06-01
EP3150599A1 (fr) 2017-04-05
PH12016501252B1 (en) 2016-08-15
MX2016010427A (es) 2016-09-22
US9889136B2 (en) 2018-02-13
PH12016501252A1 (en) 2016-08-15
US20180161331A1 (en) 2018-06-14
TR201819419T4 (tr) 2019-01-21
US10300067B2 (en) 2019-05-28
EP3150599B1 (fr) 2018-10-24
TW201617344A (zh) 2016-05-16
EP3150599A4 (fr) 2017-11-22
CA2941668A1 (fr) 2015-12-03
DK3150599T3 (en) 2019-01-14
PL3150599T3 (pl) 2019-03-29
BR112016027691B1 (pt) 2019-07-02
KR101708604B1 (ko) 2017-02-20
KR20160095660A (ko) 2016-08-11
RU2636310C1 (ru) 2017-11-22
AU2015268494B2 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
PT3381896T (pt) Composto de bifenilo ou sal do mesmo
IL248991A0 (en) Converted dihydroisoquinolinone compounds
GB201416754D0 (en) Novel compounds
GB201417002D0 (en) Novel compound
GB201417011D0 (en) Novel compounds
GB201417018D0 (en) Novel compounds
AP2016009432A0 (en) Novel compounds
SG11201604954YA (en) Novel tetrahydropyridopyrimidine compound or salt thereof
GB201405991D0 (en) Novel compounds
GB201411236D0 (en) Novel compounds
GB201411239D0 (en) Novel compounds
GB201404002D0 (en) Novel compounds
IL249356B (en) A derivative of 2-acylaminothiazole or its salt
GB201413695D0 (en) Compound
GB201412238D0 (en) Compound
GB201407694D0 (en) Compound
GB201701939D0 (en) Salt
GB201407506D0 (en) Novel compound
GB201418709D0 (en) Compound
GB201407693D0 (en) Compound
GB201416988D0 (en) Novel compound
GB201413698D0 (en) Compound
GB201417043D0 (en) Novel compounds
GB201417041D0 (en) Novel compounds
GB201414614D0 (en) Novel compounds